WeVote
Log In

Bill

Bill

S 4043

Authorizes the Bedford Hills Fire District to file an application for exemption from school and real property taxes

2025 Regular Session Introduced by Pete Harckham

NJ bill lets opioid treatment programs run medication units (satellite/mobile) with state/federal licenses, expanding access to OUD meds and clarifying patient protections.

RETURNED TO SENATE
0
WeVote Research Nonpartisan
Bill Summary · S 4043

Note on source material
- The bill number you provided (S-4043) includes two conflicting pieces of information: the title you listed (concerning the Bedford Hills Fire District and tax exemption) does not match the bill text you supplied. The text provided is an introduced New Jersey bill about substance use disorder treatment and opioid treatment programs. This summary is based on the bill text (substance use disorder treatment), which identifies the State as New Jersey and tracks the legislative actions you supplied.

Summary — Substance use disorder treatment (Introduced version of S-4043)
Purpose and intent
- To expand and modernize the regulation and delivery of opioid use disorder (OUD) treatment in New Jersey by authorizing “medication units” tied to certified opioid treatment programs (OTPs), clarifying patient protections and treatment practices, and establishing licensure standards for community-based organizations providing substance use disorder services to Medicaid recipients.

Key definitions added
- Medication for opioid use disorder: FDA‑approved medications for OUD (e.g., methadone, buprenorphine, naltrexone).
- Medication unit: A geographically separate site (brick‑and‑mortar or mobile) operated by an OTP from which licensed practitioners, contractors, or community pharmacists may dispense/administer medications, collect drug-test samples, or provide other OTP services.
- Multidisciplinary team and Opioid treatment program: defined consistent with SAMHSA certification and State licensure.

Major provisions
- Medication units
- OTPs may voluntarily establish medication units with required licensure from State (DOH, Board of Pharmacy) and federal agencies (DEA, SAMHSA).
- A medication unit must be associated with a single primary OTP that oversees operations; services not possible at the unit must be provided by the primary OTP.
- Allowed services (if privacy and space adequate): intake and initial psychosocial/medical assessments (full physical to be completed/provided within 14 days), initiation of medication‑assisted treatment (including methadone, buprenorphine, naltrexone) with appropriate medical oversight, and telecounseling by credentialed staff.
- OTPs are not required to engage/employ/contract with a pharmacist (notwithstanding contrary State law/regulation).

  • Patient protections and treatment rules

    • OTPs must provide or coordinate harm reduction services as appropriate.
    • Counseling schedules must be individualized by the multidisciplinary team.
    • Refusal of counseling alone cannot preclude a patient from receiving medication for OUD.
    • Limits administrative discharges: OTPs may not administratively discharge a patient for missed doses, non‑participation, or continued illicit substance use unless the risk of continued use is greater than the risk of overdose following treatment termination.
    • Random drug screening: OTPs may require a minimum of only eight random drug screenings per year.

  • Patient transfers between OTPs

    • Patients report to the same OTP unless prior written approval from the program physician permits temporary attendance at another OTP.
    • Conditions: referring OTP must give written notification/permission; maximum 30‑day period; take‑home dosing cannot exceed patient’s authorization at regular OTP; patient must be given positive identification for the receiving program.

  • Other statutory changes

    • Amends existing licensure/notification law regarding substance use disorder treatment centers sited within 500 feet of schools (applicant notice requirement).
    • Requires the DOH (in consultation with DHS) to establish licensure standards and provider‑enrollment requirements for community‑based organizations delivering SUD services to Medicaid recipients; such organizations must meet these standards to be reimbursed by NJ Medicaid. DOH to provide training/technical assistance.

Who is affected
- Patients with opioid use disorder in New Jersey (expanded access options, stronger protections against discharge).
- Opioid treatment programs (new pathways to operate satellite medication units and corresponding regulatory, oversight, and licensure obligations).
- Community‑based organizations seeking Medicaid reimbursement for SUD services (new licensure/enrollment standards).
- State agencies (Department of Health and Department of Human Services) and federal partners (SAMHSA, DEA) for licensing, oversight, and compliance.

Procedural / timeline notes
- Introduced Jan 14, 2025; referred to the Senate Health, Human Services and Senior Citizens Committee.
- Legislative actions indicate substitution/amendments, chamber passage activity in June 2025: passed Senate and Assembly (ordered to third reading, substituted for A46, returned to Senate). Related companion bills: A-5354 and A-46 (and prior-session A-10722).
- If enacted, DOH (with DHS) must promulgate licensure standards and training/technical assistance programs — timing for these administrative actions would be set by the agencies following enactment.

Potential impacts and considerations
- Likely increase in access to medication‑based OUD treatment (including via mobile or satellite units).
- Strengthened patient safety by limiting administrative discharges and protecting against loss of medication access for patients refusing counseling.
- Regulatory workload increase for State agencies to license medication units and set standards for community providers; coordination required with federal licensing/certification (SAMHSA, DEA).
- The provision that OTPs not be required to contract with pharmacists may affect medication dispensing practices and raises operational and safety considerations that regulators will need to address.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.